Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian equity markets trade flat
Tue, 14 Aug 11:30 am

Indian equity markets continued to trade flat during the last two hours of trade. Sectoral indices represented mixed performance. Metal and energy stocks were the top gainers while losses were led by power and healthcare stocks.

The BSE-Sensex is trading lower by 23 points and NSE-Nifty is trading down by 7 points. BSE Mid Cap and BSE Small Cap indices are trading higher by 0.1% and 0.4% respectively. The rupee is trading at 55.59 to the US dollar.

Auto stocks are trading mixed with Escorts and Eicher Motors being the top gainers while Maruti Suzuki and Tube Investments were the top losers. According to a leading financial daily, in the wake of the lockout at its Manesar plant due to which the automobile company has suffered loss in sales, Maruti Suzuki is now looking at a fast track launch of its New Alto 800. We may note here that Maruti has suffered a sales loss of Rs 20 bn so far because of the Manesar lockout. The new version of Alto will be rolled out of Maruti's Gurgaon plant and would be priced at Rs 2 lakhs. In this range, it will compete with Hyundai's Eon and Tata Motors' Nano. The automobile company believes that this launch will boost overall sales volumes.

Indian pharma stocks are trading mixed with Dishman Pharma and Panacea Biotech being the top gainers while Sun Pharma and JB Chemicals were the top losers. As per a leading daily, minority shareholders of Taro Pharma have rejected Sun Pharma's offer of US$ 39.5 per share. Grand Slam Asset Management, a minority shareholder seems to have urged other shareholders through an open letter to reject the revised offer which is 60% higher than the earlier offered price. Earlier, in October 2011, Sun Pharma which holds 66.5% stake in Taro, had made an offer of US$ 24.5 per share to acquire the remaining stake. However, the same offer was rejected stating that on the ground of improved performance of the company, the offer was inadequate. Presently, Sun Pharma stock is trading lower by 2.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets trade flat". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.